A Phase 2 interventional study of nab-sirolimus in Tumor, Tumor, Solid and Metastasis, sponsored by Aadi Bioscience, Inc.. Completed at 166 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Aadi Bioscience, Inc. · Phase 2, Interventional, and Treatment
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Study TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.
4,040 studies on the registry are indexed under Neoplasm Metastasis; 886 are open to participants now.
This study's enrollment of 128 is above the median of 50 across 3,268 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Aadi Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have a malignant solid tumor with a pathogenic inactivating TSC1 or TSC2 alteration. Genetic alterations should be identified using NGS in tumor tissue or liquid ).
Adequate liver function:
Adequate hematologic parameters:
Male or non-pregnant and non-breastfeeding female:
Exclusion Criteria:
Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with pathogenic inactivating TSC1 alterations.
Drug: nab-sirolimus
Patients with pathogenic inactivating TSC2 alterations.
Drug: nab-sirolimus
Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
Also known as: ABI-009
Overall Response Rate (ORR)
Based on CT or MRI scans from the time of study treatment initiation until disease progression, overall response rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by independent Radiographic Review (IRR). CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.
Duration of Response (DOR)
DOR is defined as the number of months from the start of CR or PR (whichever response is recorded first) and subsequently confirmed to the first date of documented progressive disease (PD) or death using CT or MRI scans in accordance with RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions. PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Disease Control Rate
Disease control rate (DCR) is defined as BOR of confirmed CR or PR (either of any duration) or SD ≥12 weeks following study treatment initiation. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.
Time to Response
Time to response (TTR) is defined as the time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Progression-free Survival
Number of months from study treatment initiation to the date of disease progression (PD) or death due to any cause PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From first dose of study treatment to the date of disease progression or death
Overall Survival
Number of months from study treatment initiation to the date of death due to any cause
Time frame: From first dose of study treatment to the date of death
Patient-Reported Outcome
Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QOQ-C30) v3.0 scores EORTC QOQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.
Time frame: D1 of every cycle up to Cycle 24
Incidence and Severity of Treatment-emergent and Treatment-related Adverse Events (AEs)
Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Time frame: Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.
Participants were enrolled from approximately 50 sites in the United States and globally (South Korea) . The first patient enrolled (consented) on 10 March 2022, with the last patient enrolled on 10 June 2024.
| Milestone | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Started | 67 | 61 |
| Completed | 0 | 0 |
| Not completed | 67 | 61 |
| Withdrew: Withdrawal by subject | 13 | 8 |
| Withdrew: Study terminated by sponsor | 26 | 23 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Death | 26 | 26 |
| Withdrew: Sponsor has closed the study. disease progression | 1 | 0 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Symptoms | 0 | 1 |
| Withdrew: Discontinue nab-sirolimus | 0 | 1 |
Based on CT or MRI scans from the time of study treatment initiation until disease progression, overall response rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by independent Radiographic Review (IRR). CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
| Percent of participants | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 9.0 (3.4 to 18.5) | 8.2 (2.7 to 18.1) |
| Efficacy Evaluable Set | 9.8 (3.7 to 20.2) | 8.9 (3.0 to 19.6) |
DOR is defined as the number of months from the start of CR or PR (whichever response is recorded first) and subsequently confirmed to the first date of documented progressive disease (PD) or death using CT or MRI scans in accordance with RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions. PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Months | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 11.84 (9.47 to 15.23) | 13.62 (3.98 to 17.34) |
| Efficacy Evaluable Set | 11.84 (9.47 to 15.23) | 13.62 (3.98 to 17.34) |
Disease control rate (DCR) is defined as BOR of confirmed CR or PR (either of any duration) or SD ≥12 weeks following study treatment initiation. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
| Percent of participants | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 34.3 (23.2 to 46.9) | 37.7 (25.6 to 51.0) |
| Efficacy Evaluable Set | 37.7 (25.6 to 51.0) | 41.1 (28.1 to 55.0) |
Time to response (TTR) is defined as the time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
| Months | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 1.43 (1.28 to 2.80) | 2.66 (2.63 to 2.99) |
| Efficacy Evaluable Set | 1.43 (1.28 to 2.80) | 2.66 (2.63 to 2.99) |
Number of months from study treatment initiation to the date of disease progression (PD) or death due to any cause PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| Months | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 4.8 (2.4 to 6.9) | 3.5 (1.9 to 5.6) |
| Efficacy Evaluable Set | 5.6 (2.8 to 6.9) | 4.0 (2.0 to 5.6) |
Number of months from study treatment initiation to the date of death due to any cause
| Months | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Full Analysis Set | 12.4 (6.9 to 17.8) | 12.4 (3.5 to NA) |
| Efficacy Evaluable Set | 12.6 (7.4 to 17.8) | 12.4 (4.1 to NA) |
Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QOQ-C30) v3.0 scores EORTC QOQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.
| Scores on a scale | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Global Health Status / QoL Baseline | 66.67 (0.0 to 91.7) | 66.67 (8.3 to 100.0) |
| Global Health Status / QoL C1D1 | — | 75.00 (75.0 to 75.0) |
| Global Health Status / QoL C2D1 | 66.67 (0.0 to 100.0) | 66.67 (16.7 to 100.0) |
| Global Health Status / QoL C3D1 | 66.67 (0.0 to 100.0) | 66.67 (0.0 to 100.0) |
| Global Health Status / QoL C4D1 | 66.67 (16.7 to 100.0) | 75.00 (50.0 to 100.0) |
| Global Health Status / QoL C5D1 | 66.67 (0.0 to 100.0) | 66.67 (16.7 to 100.0) |
| Global Health Status / QoL C6D1 | 75.0 (25.0 to 100.0) | 75.0 (25.0 to 91.7) |
| Global Health Status / QoL C7D1 | 75.0 (33.3 to 100.0) | 66.67 (33.3 to 100.0) |
| Global Health Status / QoL C8D1 | 75.0 (33.3 to 100.0) | 66.67 (50.0 to 100.0) |
| Global Health Status / QoL C9D1 | 75.0 (16.7 to 100.0) | 75.0 (33.3 to 100.0) |
| Global Health Status / QoL C10D1 | 66.67 (41.7 to 100.0) | 54.17 (41.7 to 100.0) |
| Global Health Status / QoL C11D1 | 83.33 (0.0 to 100.0) | 83.33 (50.0 to 100.0) |
| Global Health Status / QoL C12D1 | 83.33 (50.0 to 100.0) | 62.5 (41.7 to 100.0) |
| Global Health Status / QoL C13D1 | 91.67 (50.0 to 100.0) | 66.67 (58.3 to 83.3) |
| Global Health Status / QoL C14D1 | 91.67 (66.7 to 100.0) | 66.67 (50.0 to 91.7) |
| Global Health Status / QoL C15D1 | 91.67 (66.7 to 100.0) | 50.00 (33.3 to 66.7) |
| Global Health Status / QoL C16D1 | 75.00 (50.0 to 100.0) | 62.50 (0.0 to 83.3) |
| Global Health Status / QoL C17D1 | 79.17 (75.0 to 83.3) | 62.50 (8.3 to 83.3) |
| Global Health Status / QoL C18D1 | 75.00 (66.7 to 83.3) | 58.33 (33.3 to 91.7) |
| Global Health Status / QoL C19D1 | 83.3 (83.3 to 83.3) | 66.67 (50.0 to 83.3) |
| Global Health Status / QoL C20D1 | 83.3 (83.3 to 83.3) | 58.33 (33.3 to 83.3) |
| Global Health Status / QoL C21D1 | 79.17 (66.7 to 91.7) | 58.33 (33.3 to 83.3) |
| Global Health Status / QoL C22D1 | 83.34 (66.7 to 100.0) | 62.50 (33.3 to 91.7) |
| Global Health Status / QoL C23D1 | 87.50 (83.3 to 91.7) | 66.67 (50.0 to 83.3) |
| Global Health Status / QoL C24D1 | 87.50 (83.3 to 91.7) | 70.83 (58.3 to 83.3) |
| Physical Functioning / QoL Baseline | 80.00 (0 to 100.0) | 80.00 (13.3 to 100.0) |
| Physical Functioning / QoL C1D1 | — | 86.67 (86.67 to 86.67) |
| Physical Functioning / QoL C2D1 | 80.00 (6.7 to 100.0) | 73.33 (20.0 to 100.0) |
| Physical Functioning / QoL C3D1 | 86.67 (13.3 to 100.0) | 73.33 (26.7 to 100.0) |
| Physical Functioning / QoL C4D1 | 93.33 (13.3 to 100.0) | 80.0 (20.0 to 100.0) |
| Physical Functioning / QoL C5D1 | 93.33 (26.7 to 100.0) | 86.67 (25.0 to 100.0) |
| Physical Functioning / QoL C6D1 | 90.0 (6.7 to 100.0) | 86.67 (33.3 to 100.0) |
| Physical Functioning / QoL C7D1 | 93.33 (6.7 to 100.0) | 86.67 (33.3 to 100.0) |
| Physical Functioning / QoL C8D1 | 93.33 (6.7 to 100.0) | 86.67 (33.3 to 100.0) |
| Physical Functioning / QoL C9D1 | 96.67 (0.0 to 100.0) | 76.67 (60.0 to 100.0) |
| Physical Functioning / QoL C10D1 | 100.0 (33.3 to 100.0) | 83.34 (60.0 to 100.0) |
| Physical Functioning / QoL C11D1 | 93.33 (33.3 to 100.0) | 80.00 (66.7 to 100.0) |
| Physical Functioning / QoL C12D1 | 93.34 (73.3 to 100.0) | 80.0 (73.3 to 100.0) |
| Physical Functioning / QoL C13D1 | 96.67 (66.7 to 100.0) | 80.0 (53.3 to 100.0) |
| Physical Functioning / QoL C14D1 | 93.34 (86.7 to 100.0) | 80.0 (80.0 to 100.0) |
| Physical Functioning / QoL C15D1 | 93.33 (86.7 to 100.0) | 80.0 (66.7 to 93.3) |
| Physical Functioning / QoL C16D1 | 86.67 (66.7 to 100.0) | 76.67 (6.7 to 100.0) |
| Physical Functioning / QoL C17D1 | 86.67 (60.0 to 93.3) | 73.34 (0.0 to 100.0) |
| Physical Functioning / QoL C18D1 | 96.67 (93.3 to 100.0) | 60.0 (6.7 to 100.0) |
| Physical Functioning / QoL C19D1 | 93.34 (86.7 to 100.0) | 90.0 (80.0 to 100.0) |
| Physical Functioning / QoL C20D1 | 100.0 (100.0 to 100.0) | 93.34 (86.7 to 100.0) |
| Physical Functioning / QoL C21D1 | 96.67 (93.3 to 100.0) | 90.0 (80.0 to 100.0) |
| Physical Functioning / QoL C22D1 | 93.34 (86.7 to 100.0) | 90.0 (80.0 to 100.0) |
| Physical Functioning / QoL C23D1 | 93.34 (86.7 to 100.0) | 86.67 (73.3 to 100.0) |
| Physical Functioning / QoL C24D1 | 86.67 (86.67 to 86.7) | 90.0 (90.0 to 100.0) |
| Role Functioning / QoL Baseline | 83.33 (0.0 to 100.0) | 66.67 (0.0 to 100.0) |
| Role Functioning / QoL C1D1 | — | 100.0 (100.0 to 100.0) |
| Role Functioning / QoL C2D1 | 66.67 (0.0 to 100.0) | 75.00 (0.0 to 100.0) |
| Role Functioning / QoL C3D1 | 75.0 (0.0 to 100.0) | 66.67 (0.0 to 100.0) |
| Role Functioning / QoL C4D1 | 83.33 (0.0 to 100.0) | 83.33 (0.0 to 100.0) |
| Role Functioning / QoL C5D1 | 83.33 (0.0 to 100.0) | 83.33 (16.7 to 100.0) |
| Role Functioning / QoL C6D1 | 100.0 (0.0 to 100.0) | 83.33 (0.0 to 100.0) |
| Role Functioning / QoL C7D1 | 100.0 (0.0 to 100.0) | 83.33 (16.7 to 100.0) |
| Role Functioning / QoL C8D1 | 100.0 (0.0 to 100.0) | 91.67 (33.3 to 100.0) |
| Role Functioning / QoL C9D1 | 91.67 (0.0 to 100.0) | 66.67 (66.67 to 100.0) |
| Role Functioning / QoL C10D1 | 100.0 (16.7 to 100.0) | 100.0 (66.7 to 100.0) |
| Role Functioning / QoL C11D1 | 83.34 (0.0 to 100.0) | 100.0 (66.7 to 100.0) |
| Role Functioning / QoL C12D1 | 100.0 (66.7 to 100.0) | 91.67 (83.3 to 100.0) |
| Role Functioning / QoL C13D1 | 91.67 (50.0 to 100.0) | 66.67 (66.67 to 100.0) |
| Role Functioning / QoL C14D1 | 100.0 (66.7 to 100.0) | 100.0 (66.7 to 100.0) |
| Role Functioning / QoL C15D1 | 100.0 (66.7 to 100.) | 83.33 (66.7 to 83.33) |
| Role Functioning / QoL C16D1 | 91.67 (66.7 to 100.0) | 83.34 (0.0 to 100.0) |
| Role Functioning / QoL C17D1 | 100.0 (66.7 to 100.0) | 83.34 (0.0 to 100.0) |
| Role Functioning / QoL C18D1 | 83.34 (66.7 to 100.0) | 66.67 (0.0 to 100.0) |
| Role Functioning / QoL C19D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Role Functioning / QoL C20D1 | 100.0 (100.0 to 100.0) | 91.67 (83.3 to 100.0) |
| Role Functioning / QoL C21D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Role Functioning / QoL C22D1 | 83.33 (83.33 to 83.33) | 83.34 (66.7 to 100.0) |
| Role Functioning / QoL C23D1 | 66.67 (66.67 to 66.67) | 83.34 (66.7 to 100.0) |
| Role Functioning / QoL C24D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Emotional Functioning / QoL Baseline | 83.33 (0.0 to 100.0) | 83.33 (41.7 to 100.0) |
| Emotional Functioning / QoL C1D1 | — | 75.0 (75.0 to 75.0) |
| Emotional Functioning / QoL C2D1 | 83.33 (0.0 to 100.0) | 91.67 (33.3 to 100.0) |
| Emotional Functioning / QoL C3D1 | 87.5 (0.0 to 100.0) | 83.33 (25.0 to 100.0) |
| Emotional Functioning / QoL C4D1 | 91.67 (50.0 to 100.0) | 91.67 (41.7 to 100.0) |
| Emotional Functioning / QoL C5D1 | 91.67 (33.3 to 100.0) | 83.33 (41.7 to 100.0) |
| Emotional Functioning / QoL C6D1 | 91.67 (50.0 to 100.0) | 91.67 (25.0 to 100.0) |
| Emotional Functioning / QoL C7D1 | 91.67 (0.0 to 100.0) | 100.00 (58.3 to 100.0) |
| Emotional Functioning / QoL C8D1 | 83.33 (66.7 to 100.0) | 83.33 (66.7 to 100.0) |
| Emotional Functioning / QoL C9D1 | 95.84 (33.3 to 100.0) | 91.67 (50.0 to 100.0) |
| Emotional Functioning / QoL C10D1 | 91.67 (66.7 to 100.0) | 83.33 (75.0 to 100.0) |
| Emotional Functioning / QoL C11D1 | 95.84 (66.7 to 100.0) | 83.33 (66.7 to 100.0) |
| Emotional Functioning / QoL C12D1 | 100.0 (83.3 to 100.0) | 91.67 (66.7 to 100.0) |
| Emotional Functioning / QoL C13D1 | 100.0 (83.3 to 100.0) | 83.33 (75.0 to 100.0) |
| Emotional Functioning / QoL C14D1 | 100.0 (75.0 to 100.0) | 75.0 (75.0 to 100.0) |
| Emotional Functioning / QoL C15D1 | 100.0 (66.7 to 100.0) | 75.0 (75.0 to 83.3) |
| Emotional Functioning / QoL C16D1 | 100.0 (75.0 to 100.0) | 75.0 (33.3 to 100.0) |
| Emotional Functioning / QoL C17D1 | 75.00 (75.0 to 75.0) | 70.83 (50.0 to 100.0) |
| Emotional Functioning / QoL C18D1 | 87.5 (75.0 to 100.0) | 66.67 (8.3 to 100.0) |
| Emotional Functioning / QoL C19D1 | 95.84 (91.7 to 100.0) | 87.5 (75.0 to 100.0) |
| Emotional Functioning / QoL C20D1 | 83.34 (66.7 to 100.0) | 91.67 (83.3 to 100.0) |
| Emotional Functioning / QoL C21D1 | 87.5 (75.0 to 100.0) | 87.5 (75.0 to 100.0) |
| Emotional Functioning / QoL C22D1 | 95.84 (91.7 to 100.0) | 91.67 (83.3 to 100.0) |
| Emotional Functioning / QoL C23D1 | 75.00 (58.3 to 91.7) | 83.34 (66.7 to 100.0) |
| Emotional Functioning / QoL C24D1 | 70.83 (58.3 to 83.3) | 83.34 (66.7 to 100.0) |
| Cognitive Functioning / QoL Baseline | 83.33 (0.0 to 100.0) | 83.33 (33.3 to 100.0) |
| Cognitive Functioning / QoL C1D1 | — | 83.33 (83.33 to 83.33) |
| Cognitive Functioning / QoL C2D1 | 83.33 (0.0 to 100.0) | 83.33 (16.7 to 100.0) |
| Cognitive Functioning / QoL C3D1 | 83.33 (0.0 to 100.0) | 83.33 (16.7 to 100.0) |
| Cognitive Functioning / QoL C4D1 | 100.00 (16.7 to 100.0) | 83.33 (33.3 to 100.0) |
| Cognitive Functioning / QoL C5D1 | 100.00 (16.7 to 100.0) | 91.67 (16.7 to 100.0) |
| Cognitive Functioning / QoL C6D1 | 100.00 (16.7 to 100.0) | 100.0 (33.3 to 100.0) |
| Cognitive Functioning / QoL C7D1 | 83.33 (0.0 to 100.0) | 100.0 (33.3 to 100.0) |
| Cognitive Functioning / QoL C8D1 | 100.0 (50.0 to 100.0) | 83.33 (50.0 to 100.0) |
| Cognitive Functioning / QoL C9D1 | 100.0 (33.3 to 100.0) | 91.67 (33.3 to 100.0) |
| Cognitive Functioning / QoL C10D1 | 100.0 (33.3 to 100.0) | 91.67 (66.7 to 100.0) |
| Cognitive Functioning / QoL C11D1 | 100.0 (33.3 to 100.0) | 66.67 (50.0 to 100.0) |
| Cognitive Functioning / QoL C12D1 | 100.0 (83.3 to 100.0) | 91.67 (83.3 to 100.0) |
| Cognitive Functioning / QoL C13D1 | 100.0 (66.7 to 100.0) | 83.33 (66.7 to 100.0) |
| Cognitive Functioning / QoL C14D1 | 100.0 (100.0 to 100.0) | 91.67 (66.7 to 100.0) |
| Cognitive Functioning / QoL C15D1 | 100.0 (83.3 to 100.0) | 83.33 (50.0 to 83.33) |
| Cognitive Functioning / QoL C16D1 | 100.0 (100.0 to 100.0) | 66.67 (50.0 to 100.0) |
| Cognitive Functioning / QoL C17D1 | 100.0 (100.0 to 100.0) | 91.67 (33.3 to 100.0) |
| Cognitive Functioning / QoL C18D1 | 100.0 (100.0 to 100.0) | 66.67 (33.3 to 100.0) |
| Cognitive Functioning / QoL C19D1 | 100.0 (100.0 to 100.0) | 75.0 (50.0 to 100.0) |
| Cognitive Functioning / QoL C20D1 | 100.0 (100.0 to 100.0) | 91.67 (83.3 to 100.0) |
| Cognitive Functioning / QoL C21D1 | 100.0 (100.0 to 100.0) | 91.67 (83.3 to 100.0) |
| Cognitive Functioning / QoL C22D1 | 100.0 (100.0 to 100.0) | 91.67 (83.3 to 100.0) |
| Cognitive Functioning / QoL C23D1 | 91.67 (83.3 to 100.0) | 83.34 (66.7 to 100.0) |
| Cognitive Functioning / QoL C24D1 | 91.67 (83.3 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL Baseline | 66.67 (0.0 to 100.0) | 83.33 (0.0 to 100.0) |
| Social Functioning / QoL C1D1 | — | 100.0 (100.0 to 100.0) |
| Social Functioning / QoL C2D1 | 83.33 (0.0 to 100.0) | 83.33 (33.3 to 100.0) |
| Social Functioning / QoL C3D1 | 66.67 (0.0 to 100.0) | 83.33 (0.0 to 100.0) |
| Social Functioning / QoL C4D1 | 83.33 (0.0 to 100.0) | 83.33 (33.3 to 100.0) |
| Social Functioning / QoL C5D1 | 83.33 (0.0 to 100.0) | 91.67 (33.3 to 100.0) |
| Social Functioning / QoL C6D1 | 83.33 (33.3 to 100.0) | 83.33 (50.0 to 100.0) |
| Social Functioning / QoL C7D1 | 100.0 (0.0 to 100.0) | 100.0 (33.3 to 100.0) |
| Social Functioning / QoL C8D1 | 100.0 (33.3 to 100.0) | 100.0 (33.3 to 100.0) |
| Social Functioning / QoL C9D1 | 83.33 (16.7 to 100.0) | 100.0 (50.0 to 100.0) |
| Social Functioning / QoL C10D1 | 100.0 (16.7 to 100.0) | 100.0 (66.7 to 100.0) |
| Social Functioning / QoL C11D1 | 91.67 (33.3 to 100.0) | 83.33 (66.7 to 100.0) |
| Social Functioning / QoL C12D1 | 91.67 (66.7 to 100.0) | 91.67 (66.7 to 100.0) |
| Social Functioning / QoL C13D1 | 100.0 (66.7 to 100.0) | 66.67 (66.67 to 100.0) |
| Social Functioning / QoL C14D1 | 91.67 (66.7 to 100.0) | 66.67 (66.67 to 100.0) |
| Social Functioning / QoL C15D1 | 100.0 (83.3 to 100.0) | 66.67 (66.67 to 83.3) |
| Social Functioning / QoL C16D1 | 91.67 (66.7 to 100.0) | 66.67 (16.7 to 100.0) |
| Social Functioning / QoL C17D1 | 91.67 (83.3 to 100.0) | 66.67 (0.0 to 100.0) |
| Social Functioning / QoL C18D1 | 83.34 (66.7 to 100.0) | 66.67 (0.0 to 100.0) |
| Social Functioning / QoL C19D1 | 91.67 (83.3 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL C20D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL C21D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL C22D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL C23D1 | 83.34 (66.7 to 100.0) | 83.34 (66.7 to 100.0) |
| Social Functioning / QoL C24D1 | 91.67 (83.3 to 100.0) | 83.34 (66.7 to 100.0) |
| Fatigue / QoL Baseline | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Fatigue / QoL C1D1 | — | 22.22 (22.22 to 22.22) |
| Fatigue / QoL C2D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 88.9) |
| Fatigue / QoL C3D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Fatigue / QoL C4D1 | 22.22 (0.0 to 100.0) | 33.33 (0.0 to 77.8) |
| Fatigue / QoL C5D1 | 22.22 (0.0 to 100.0) | 33.33 (0.0 to 77.8) |
| Fatigue / QoL C6D1 | 27.78 (0.0 to 100.0) | 33.33 (0.0 to 77.8) |
| Fatigue / QoL C7D1 | 33.33 (0.0 to 100.0) | 22.22 (11.1 to 66.7) |
| Fatigue / QoL C8D1 | 22.22 (0.0 to 100.0) | 27.78 (0.0 to 66.7) |
| Fatigue / QoL C9D1 | 22.22 (0.0 to 100.0) | 22.22 (0.0 to 33.3) |
| Fatigue / QoL C10D1 | 22.22 (0.0 to 66.7) | 22.22 (0.0 to 44.4) |
| Fatigue / QoL C11D1 | 16.67 (0.0 to 66.7) | 22.22 (0.0 to 66.7) |
| Fatigue / QoL C12D1 | 16.67 (0.0 to 44.4) | 11.11 (0.0 to 33.3) |
| Fatigue / QoL C13D1 | 11.11 (0.0 to 55.6) | 22.22 (0.0 to 33.3) |
| Fatigue / QoL C14D1 | 5.56 (0.0 to 33.3) | 22.22 (0.0 to 33.3) |
| Fatigue / QoL C15D1 | 22.22 (0.0 to 33.3) | 22.22 (22.2 to 33.3) |
| Fatigue / QoL C16D1 | 22.22 (11.1 to 33.3) | 22.22 (0.0 to 88.9) |
| Fatigue / QoL C17D1 | 33.33 (33.33 to 33.33) | 27.78 (0.0 to 88.9) |
| Fatigue / QoL C18D1 | 33.33 (22.2 to 44.4) | 33.33 (0.0 to 100.0) |
| Fatigue / QoL C19D1 | 27.78 (22.2 to 33.3) | 16.67 (0.0 to 33.3) |
| Fatigue / QoL C20D1 | 27.78 (22.2 to 33.3) | 16.67 (11.1 to 22.2) |
| Fatigue / QoL C21D1 | 27.78 (22.2 to 33.3) | 11.11 (0.0 to 22.2) |
| Fatigue / QoL C22D1 | 11.11 (0.0 to 22.2) | 16.67 (0.0 to 33.3) |
| Fatigue / QoL C23D1 | 22.22 (22.22 to 22.22) | 16.67 (0.0 to 33.3) |
| Fatigue / QoL C24D1 | 11.11 (0.0 to 22.2) | 16.67 (0.0 to 33.3) |
| Nausea / Vomiting / QoL Baseline | 0.00 (0.0 to 50.0) | 0.00 (0.0 to 100.0) |
| Nausea / Vomiting / QoL C1D1 | — | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C2D1 | 0.00 (0.0 to 100.0) | 0.00 (0.0 to 100.0) |
| Nausea / Vomiting / QoL C3D1 | 0.00 (0.0 to 100.0) | 0.00 (0.0 to 66.7) |
| Nausea / Vomiting / QoL C4D1 | 0.00 (0.0 to 66.7) | 0.00 (0.0 to 50.0) |
| Nausea / Vomiting / QoL C5D1 | 0.00 (0.0 to 33.3) | 0.00 (0.0 to 33.3) |
| Nausea / Vomiting / QoL C6D1 | 0.00 (0.0 to 33.3) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C7D1 | 0.00 (0.0 to 66.7) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C8D1 | 0.00 (0.0 to 33.3) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C9D1 | 0.00 (0.0 to 16.7) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C10D1 | 0.00 (0.0 to 16.7) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C11D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C12D1 | 0.00 (0.0 to 33.3) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C13D1 | 0.00 (0.0 to 16.7) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C14D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C15D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C16D1 | 0.00 (0.0 to 16.7) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C17D1 | 0.00 (0.0 to 16.7) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C18D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C19D1 | 0.00 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Nausea / Vomiting / QoL C20D1 | 8.34 (0.0 to 16.7) | 8.34 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C21D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C22D1 | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| Nausea / Vomiting / QoL C23D1 | 0.00 (0.0 to 0.0) | 8.34 (0.0 to 16.7) |
| Nausea / Vomiting / QoL C24D1 | 0.00 (0.0 to 0.0) | 8.34 (0.0 to 16.7) |
| Pain / QoL Baseline | 16.67 (0.0 to 100.0) | 16.67 (0.0 to 100.0) |
| Pain / QoL C1D1 | — | 0.00 (0.0 to 0.0) |
| Pain / QoL C2D1 | 33.33 (0.0 to 100.0) | 16.67 (0.0 to 100.0) |
| Pain / QoL C3D1 | 25.00 (0.0 to 100.0) | 16.67 (0.0 to 100.0) |
| Pain / QoL C4D1 | 16.67 (0.0 to 100.0) | 16.67 (0.0 to 100.0) |
| Pain / QoL C5D1 | 0.00 (0.0 to 66.7) | 16.67 (0.0 to 83.3) |
| Pain / QoL C6D1 | 8.34 (0.0 to 100.0) | 33.33 (0.0 to 83.3) |
| Pain / QoL C7D1 | 16.67 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Pain / QoL C8D1 | 0.00 (0.0 to 100.0) | 8.34 (0.0 to 83.3) |
| Pain / QoL C9D1 | 8.34 (0.0 to 100.0) | 8.34 (0.0 to 50.0) |
| Pain / QoL C10D1 | 0.00 (0.0 to 100.0) | 16.67 (0.0 to 33.3) |
| Pain / QoL C11D1 | 16.67 (0.0 to 33.3) | 33.33 (0.0 to 66.7) |
| Pain / QoL C12D1 | 8.34 (0.0 to 33.3) | 0.00 (0.0 to 33.3) |
| Pain / QoL C13D1 | 0.00 (0.0 to 33.3) | 33.33 (0.0 to 50.0) |
| Pain / QoL C14D1 | 0.00 (0.0 to 16.7) | 16.67 (0.0 to 33.3) |
| Pain / QoL C15D1 | 16.67 (0.0 to 33.3) | 33.33 (16.7 to 50.0) |
| Pain / QoL C16D1 | 0.00 (0.0 to 66.7) | 41.67 (0.0 to 100.0) |
| Pain / QoL C17D1 | 16.67 (0.0 to 33.3) | 33.33 (0.0 to 100.0) |
| Pain / QoL C18D1 | 8.34 (0.0 to 16.7) | 33.33 (0.0 to 100.0) |
| Pain / QoL C19D1 | 8.34 (0.0 to 16.7) | 16.67 (0.0 to 33.3) |
| Pain / QoL C20D1 | 16.67 (0.0 to 33.3) | 25.00 (0.0 to 50.0) |
| Pain / QoL C21D1 | 16.67 (0.0 to 33.3) | 8.34 (0.0 to 16.7) |
| Pain / QoL C22D1 | 8.34 (0.0 to 16.7) | 16.67 (0.0 to 33.3) |
| Pain / QoL C23D1 | 25.00 (0.0 to 50.0) | 25.00 (0.0 to 50.0) |
| Pain / QoL C24D1 | 25.00 (0.0 to 50.0) | 16.67 (0.0 to 33.3) |
| Dyspnoea / QoL Baseline | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Dyspnoea / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C2D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 100.0) |
| Dyspnoea / QoL C3D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Dyspnoea / QoL C4D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C5D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 100.0) |
| Dyspnoea / QoL C6D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 66.7) |
| Dyspnoea / QoL C7D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 66.7) |
| Dyspnoea / QoL C8D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C9D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C10D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C11D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C12D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C13D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C14D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C15D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C16D1 | 0.0 (0.0 to 33.3) | 16.67 (0.0 to 66.7) |
| Dyspnoea / QoL C17D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Dyspnoea / QoL C18D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C19D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C20D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C21D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C22D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C23D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Dyspnoea / QoL C24D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Insomnia / QoL Baseline | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Insomnia / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Insomnia / QoL C2D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Insomnia / QoL C3D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Insomnia / QoL C4D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 66.7) |
| Insomnia / QoL C5D1 | 33.33 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Insomnia / QoL C6D1 | 0.0 (0.0 to 100.0) | 33.33 (0.0 to 66.7) |
| Insomnia / QoL C7D1 | 33.33 (0.0 to 100.0) | 33.33 (0.0 to 66.7) |
| Insomnia / QoL C8D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Insomnia / QoL C9D1 | 0.0 (0.0 to 100.0) | 33.33 (0.0 to 33.33) |
| Insomnia / QoL C10D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Insomnia / QoL C11D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 66.7) |
| Insomnia / QoL C12D1 | 0.0 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Insomnia / QoL C13D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Insomnia / QoL C14D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Insomnia / QoL C15D1 | 0.0 (0.0 to 33.3) | 33.33 (0.0 to 33.33) |
| Insomnia / QoL C16D1 | 16.67 (0.0 to 66.7) | 33.33 (0.0 to 100.0) |
| Insomnia / QoL C17D1 | 33.33 (33.33 to 33.33) | 16.67 (0.0 to 100.0) |
| Insomnia / QoL C18D1 | 16.67 (0.0 to 33.3) | 33.33 (0.0 to 66.7) |
| Insomnia / QoL C19D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Insomnia / QoL C20D1 | 33.33 (33.33 to 33.33) | 16.67 (0.0 to 33.3) |
| Insomnia / QoL C21D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Insomnia / QoL C22D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Insomnia / QoL C23D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Insomnia / QoL C24D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Appetite Loss / QoL Baseline | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Appetite Loss / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C2D1 | 33.3 (0.0 to 100.0) | 33.33 (0.0 to 100.0) |
| Appetite Loss / QoL C3D1 | 33.33 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Appetite Loss / QoL C4D1 | 16.67 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Appetite Loss / QoL C5D1 | 33.33 (0.0 to 66.7) | 0.0 (0.0 to 100.0) |
| Appetite Loss / QoL C6D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 66.7) |
| Appetite Loss / QoL C7D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 66.7) |
| Appetite Loss / QoL C8D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 100.0) |
| Appetite Loss / QoL C9D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Appetite Loss / QoL C10D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C11D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C12D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C13D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C14D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C15D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Appetite Loss / QoL C16D1 | 16.67 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Appetite Loss / QoL C17D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C18D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Appetite Loss / QoL C19D1 | 16.67 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Appetite Loss / QoL C20D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C21D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Appetite Loss / QoL C22D1 | 16.67 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Appetite Loss / QoL C23D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Appetite Loss / QoL C24D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Constipation / QoL Baseline | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Constipation / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Constipation / QoL C2D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Constipation / QoL C3D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Constipation / QoL C4D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C5D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C6D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C7D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C8D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 66.7) |
| Constipation / QoL C9D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 66.7) |
| Constipation / QoL C10D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C11D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C12D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C13D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Constipation / QoL C14D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C15D1 | 0.0 (0.0 to 0.0) | 33.33 (0.0 to 66.7) |
| Constipation / QoL C16D1 | 16.67 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Constipation / QoL C17D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 66.7) |
| Constipation / QoL C18D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 66.7) |
| Constipation / QoL C19D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C20D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C21D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C22D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C23D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Constipation / QoL C24D1 | 16.67 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Diarhoea / QoL Baseline | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 66.7) |
| Diarhoea / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Diarhoea / QoL C2D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 100.0) |
| Diarhoea / QoL C3D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Diarhoea / QoL C4D1 | 0.0 (0.0 to 66.7) | 33.33 (0.0 to 66.7) |
| Diarhoea / QoL C5D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C6D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C7D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 66.7) |
| Diarhoea / QoL C8D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C9D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C10D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C11D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C12D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C13D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C14D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C15D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Diarhoea / QoL C16D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C17D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Diarhoea / QoL C18D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 66.7) |
| Diarhoea / QoL C19D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Diarhoea / QoL C20D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Diarhoea / QoL C21D1 | 33.34 (0.0 to 66.7) | 16.67 (0.0 to 33.3) |
| Diarhoea / QoL C22D1 | 0.0 (0.0 to 0.0) | 33.34 (0.0 to 66.7) |
| Diarhoea / QoL C23D1 | 16.67 (0.0 to 33.3) | 33.34 (0.0 to 66.7) |
| Diarhoea / QoL C24D1 | 0.0 (0.0 to 0.0) | 16.67 (0.0 to 33.3) |
| Financial Problems / QoL Baseline | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Financial Problems / QoL C1D1 | — | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C2D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 66.7) |
| Financial Problems / QoL C3D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Financial Problems / QoL C4D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 100.0) |
| Financial Problems / QoL C5D1 | 0.0 (0.0 to 100.0) | 16.67 (0.0 to 100.0) |
| Financial Problems / QoL C6D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 66.7) |
| Financial Problems / QoL C7D1 | 0.0 (0.0 to 100.0) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C8D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 100.0) |
| Financial Problems / QoL C9D1 | 0.0 (0.0 to 66.7) | 0.0 (0.0 to 66.7) |
| Financial Problems / QoL C10D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C11D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C12D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C13D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 66.7) |
| Financial Problems / QoL C14D1 | 0.0 (0.0 to 33.3) | 16.67 (0.0 to 33.3) |
| Financial Problems / QoL C15D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C16D1 | 0.0 (0.0 to 33.3) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C17D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 33.3) |
| Financial Problems / QoL C18D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C19D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C20D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C21D1 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C22D1 | 16.67 (0.0 to 33.3) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C23D1 | 33.34 (0.0 to 66.7) | 0.0 (0.0 to 0.0) |
| Financial Problems / QoL C24D1 | 33.34 (0.0 to 66.7) | 0.0 (0.0 to 0.0) |
Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
| Participants | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Any TEAEs | 67 | 61 |
| Any related TEAEs | 60 | 55 |
| Any treatment-emergent SAEs | 35 | 29 |
| Any treatment-emergent related SAEs | 12 | 10 |
| Any Grade 3 or 4 TEAEs | 50 | 44 |
| Any Grade 3 or 4 related TEAEs | 37 | 32 |
Collected over Monitored continuously with onset on or after the first dose of study drug through last dose of study drug (estimated up to 30 months) plus safety follow-up of 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Pathogenic Inactivating TSC1 Alterations | 26/67 (38.8%) | 35/67 (52.2%) | 67/67 (100%) |
| Arm B: Pathogenic Inactivating TSC2 Alterations | 26/61 (42.6%) | 29/61 (47.5%) | 61/61 (100%) |
| Event | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| Urinary tract infectionInfections and infestations | 5/67 | 0/61 |
| Acute kidney injuryRenal and urinary disorders | 3/67 | 4/61 |
| PneumoniaInfections and infestations | 3/67 | 2/61 |
| SepsisInfections and infestations | 3/67 | 2/61 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/67 | 1/61 |
| NauseaGastrointestinal disorders | 1/67 | 2/61 |
| COVID-19 pneumoniaInfections and infestations | 2/67 | 0/61 |
| Abdominal painGastrointestinal disorders | 2/67 | 1/61 |
| ConstipationGastrointestinal disorders | 2/67 | 0/61 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/67 | 0/61 |
| Event | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 32/67 | 10/61 |
| FatigueGeneral disorders | 30/67 | 24/61 |
| Decreased appetiteMetabolism and nutrition disorders | 28/67 | 12/61 |
| NauseaGastrointestinal disorders | 25/67 | 19/61 |
| DiarrhoeaGastrointestinal disorders | 24/67 | 17/61 |
| StomatitisGastrointestinal disorders | 21/67 | 18/61 |
| HypokalaemiaMetabolism and nutrition disorders | 21/67 | 13/61 |
| Weight decreasedInvestigations | 18/67 | 11/61 |
| DysgeusiaNervous system disorders | 18/67 | 8/61 |
| ConstipationGastrointestinal disorders | 17/67 | 14/61 |
| Age, Customized(Participants) | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations | Total |
|---|---|---|---|
| Age — <65 years | 34 | 34 | 68 |
| Age — 65-74 years | 23 | 18 | 41 |
| Age — > = 75 years | 10 | 9 | 19 |
| Sex: Female, Male(Participants) | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations | Total |
|---|---|---|---|
| Female | 41 | 36 | 77 |
| Male | 26 | 25 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 8 | 12 |
| Not Hispanic or Latino | 61 | 53 | 114 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Arm A: Pathogenic Inactivating TSC1 Alterations | Arm B: Pathogenic Inactivating TSC2 Alterations | Total |
|---|---|---|---|
| Race — White | 46 | 45 | 91 |
| Race — Asian | 13 | 13 | 26 |
| Race — Not Applicable | 4 | 2 | 6 |
| Race — Black or African American | 3 | 1 | 4 |
| Race — Other | 1 | 0 | 1 |
Showing the first 100 of 166 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus Albumin-bound Nanoparticles
Aadi Bioscience, Inc.